What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents

CytoSorbents Corporation -3.63%

CytoSorbents Corporation




HC Wainwright & Co. downgraded its rating of CytoSorbents (NASDAQ:CTSO) to Neutral with a price target of $1.00, changing its price target from $5.50 to $1.00.

Shares of CytoSorbents are trading down 5.07% over the last 24 hours, at $1.03 per share.

A move to $1.00 would account for a 2.91% decline from the current share price.

About CytoSorbents

CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via